Detection of P. aeruginosa harboring $bla_{CTX-M-2}$, $bla_{GES-1}$ and $bla_{GES-5}$, $bla_{IMP-1}$ and $bla_{SPM-1}$ causing infections in Brazilian tertiary-care hospital

Milena Polotto$^{1,2}$, Tiago Casella$^{1,2}$, Maria Gabriela de Lucca Oliveira$^3$, Fernando G Rúbio$^1$, Mauricio L Nogueira$^4$, Margarete TG de Almeida$^1$ and Mara CL Nogueira$^1$$^*$

Abstract

**Background:** Nosocomial infections caused by *Pseudomonas aeruginosa* presenting resistance to beta-lactam drugs are one of the most challenging targets for antimicrobial therapy, leading to substantial increase in mortality rates in hospitals worldwide. In this context, *P. aeruginosa* harboring acquired mechanisms of resistance, such as production of metallo-beta-lactamase (MBLs) and extended-spectrum beta-lactamases (ESBLs) have the highest clinical impact. Hence, this study was designed to investigate the presence of genes codifying for MBLs and ESBLs among carbapenem resistant *P. aeruginosa* isolated in a Brazilian 720-bed teaching tertiary care hospital.

**Methods:** Fifty-six carbapenem-resistant *P. aeruginosa* strains were evaluated for the presence of MBL and ESBL genes. Strains presenting MBL and/or ESBL genes were submitted to pulsed-field gel electrophoresis for genetic similarity evaluation.

**Results:** Despite the carbapenem resistance, genes for MBLs ($bla_{SPM-1}$ or $bla_{IMP-1}$) were detected in only 26.7% of isolates. Genes encoding ESBLs were detected in 23.2% of isolates. The $bla_{CTX-M-2}$ was the most prevalent ESBL gene (19.6%), followed by $bla_{GES-1}$ and $bla_{GES-5}$ detected in one isolate each. In all isolates presenting MBL phenotype by double-disc synergy test (DDST), the $bla_{SPM-1}$ or $bla_{IMP-1}$ genes were detected. In addition, $bla_{IMP-1}$ was also detected in three isolates which did not display any MBL phenotype. These isolates also presented the $bla_{CTX-M-2}$ gene. The co-existence of $bla_{CTX-M-2}$ with $bla_{IMP-1}$ is presently reported for the first time, as like as co-existence of $bla_{GES-1}$ with $bla_{IMP-1}$.

**Conclusions:** In this study MBLs production was not the major mechanism of resistance to carbapenems, suggesting the occurrence of multidrug efflux pumps, reduction in porin channels and production of other beta-lactamases. The detection of $bla_{CTX-M-2}$, $bla_{GES-1}$ and $bla_{GES-5}$ reflects the recent emergence of ESBLs among antimicrobial resistant *P. aeruginosa* and the extraordinary ability presented by this pathogen to acquire multiple resistance mechanisms. These findings raise the concern about the future of antimicrobial therapy and the capability of clinical laboratories to detect resistant strains, since simultaneous production of MBLs and ESBLs is known to promote further complexity in phenotypic detection. Occurrence of intra-hospital clonal dissemination enhances the necessity of better observance of infection control practices.

**Keywords:** *P. aeruginosa*, Nosocomial infection, ESBL, MBL, CTX-M-2, GES-1, GES-5, IMP-1, SPM-1

* Correspondence: ml.nogueira@famerp.br
$^1$Laboratório de Microbiologia. Departamento de Doenças Dermatológicas, Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP, Brazil
Full list of author information is available at the end of the article

© 2012 Polotto et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

*Pseudomonas aeruginosa* is an opportunistic pathogen responsible for a large spectrum of invasive diseases in healthcare settings, including pneumonia, urinary tract infections and bacteremia [1]. For such infections, antimicrobial therapy may become a difficult task, because *Pseudomonas aeruginosa* is naturally resistant to many drugs, and presents a remarkable ability to acquire further resistance mechanisms to multiple classes of antimicrobial agents, even during the course of a treatment [2]. In this context, infections by *P. aeruginosa* presenting acquired resistance to beta-lactam drugs are considered one of the most challenging targets for antimicrobial therapy [3], being responsible for high rates of therapeutic failure, increase in mortality, morbidity, and in overall cost of treatment [4-6].

The Ambler’s class B beta-lactamases (metallo-beta-lactamases – MBLs) and class A extended-spectrum beta-lactamases (ESBLs) are acquired resistance determinants that present high clinical impact [7,8]. These enzymes, usually codified by genes associated with mobile genetic elements, are matter of major concern with regard to the future of antimicrobial chemotherapy because of its remarkable dissemination capability [9].

MBLs such as IMP, VIM, SPM, GIM and AIM represent the leading acquired mechanism of resistance to beta-lactams in *P. aeruginosa*. These enzymes hydrolyze the majority of beta-lactam drugs [10] and compromise clinical utility of carbapenems, the most potent agents for treating severe infections caused by multidrug resistant strains [11]. More recently, appearance of ESBLs such as TEM, SHV, CTX-M, BEL, PER, VEB, GES, PME and OXA-type beta-lactamases has become an emergent public health problem, since these enzymes confer resistance to at least all expanded spectrum cephalosporins and compromise efficiency of ceftazidime, an important antibiotic regimen for *P. aeruginosa* [12-14].

For the establishment of the appropriate antimicrobial therapy and for assessment and control of the spread of drug resistant *P. aeruginosa*, the molecular detection and surveillance of resistance genes is becoming increasingly important [15,16]. Despite of this, epidemiological data reporting the prevalence of MBL and ESBL producing *P. aeruginosa* is sparse, due to the inexistence of standardized methods for phenotypic detection of ESBL and MBL production [7,17] and the complexity for the implementation of PCR based methods in the routine of clinical laboratories [17]. In order to overcome this difficulty, a number of commercial rapid molecular tests are being developed that identify pathogens and the presence of genetic determinants of antimicrobial resistance [18,19]. The association of such new technologies with current classical methods may improve the ability of clinical laboratories to provide accurate and fast results that will impact on patient care.

Hence, this study was performed to investigate the carriage of genes codifying MBLs and ESBLs by *P. aeruginosa* isolated from patients admitted to a Brazilian 720-bed teaching tertiary care hospital. Despite the high rates of carbapenem resistance, genes for MBLs production were not observed in the majority of the isolates. Notably ESBLs codifying genes *bla<sub>CTX-M-2</sub>, bla<sub>GES-1</sub> and *bla<sub>GES-5</sub>* were detected in several strains, and the coexistence of *bla<sub>CTX-M-2</sub>* with *bla<sub>IMP-1</sub>* and *bla<sub>GES-1</sub>* with *bla<sub>IMP-1</sub>* in *P. aeruginosa* was observed, and is presently reported for the first time. These findings underline the emergence of class A extended-spectrum beta-lactamases among *P. aeruginosa*.

Methods

Bacterial isolates

In this study were included a total of 56 *P. aeruginosa* isolates resistant to ceftazidime, imipenem and/or meropenem, nonrepetitively obtained from patients admitted to a teaching hospital in São Paulo State, Brazil, over a period between June to December 2009. Isolates were obtained from specimens originated from urinary tract, respiratory tract, bloodstream and soft tissue. Clinical specimens were collected in intensive care units, clinical and surgical wards as well as from outpatients as a standard care procedure and were stored for this work. This study was approved by the Ethical Review Board from our institution (Comitê de Ética em Pesquisa – FAMERP) under protocol # 3131/2009.

Susceptibility testing and phenotypic detection of MBL production

Antimicrobial susceptibility to aztreonam, ceftazidime, cefepine, imipenem, meropenem, piperacillin/tazobac- tam, amikacin, gentamicin, ciprofloxacin, levofloxacin and polymyxin B were determined by the disk diffusion method, following Clinical and Laboratory Standards Institute recommendations [20]. Phenotypic detection of MBLs was performed by double-disc synergy test (DDST) using the 2-mercaptopropionic acid as a MBL inhibitor [17].

Genotypic detection of MBL and ESBL genes

Specific primers and protocols were used to detect and sequence *bla<sub>TEM</sub>, bla<sub>SHV</sub>, bla<sub>CTX-M</sub>, *bla<sub>GES</sub>, bla<sub>KPC</sub>, bla<sub>IMP</sub> and *bla<sub>VIM</sub>* [17,21-24]. The detection and sequencing of *bla<sub>SPM-1</sub>* was performed using primers previously described [25] and also others specifically designed for this study using DS Gene 2.0 Software (Accelrys, USA). PCR products were purified in ethanol according to previously described methodology [26] and subjected to direct sequencing with the ABI PRISM 3130 automated
sequencer (Applied Biosystems, Foster City, CA). The products were aligned with Accelrys Gene 2.0 (Accelrys Software Inc. 2006). Database similarity searches were run with BLAST at the National Center for Biotechnology Information website (http://www.ncbi.nlm.nih.gov).

Molecular typing
Genetic relatedness was evaluated by pulsed-field gel electrophoresis (PFGE) using SpeI (Fermentas Life Sciences, MD, EUA) with a CHEF-DR II apparatus (BioRad, Richmond, CA, EUA) as described elsewhere [27]. BioNumerics software (Applied Maths) was used for dendrogram construction and clustering, based on the band-based Dice similarity coefficient and using the unweighted pair group method (UPGMA) using arithmetic averages. Isolates were considered to belong to the same cluster when similarity coefficient was 90% [28]. The visual Tenover criteria were also applied [29].

Results
A total of 80.3% (45/56) of isolates were resistant to the combination piperacillin/tazobactam, 62.5% (35/56) to aztreonam, 78.6% (44/56) to cefazidime, 96.4% (54/56) to cefepime, 96.4% (54/56) to imipenem, 75.0% (42/56) to meropenem, 51.8% (29/56) to amikacin, 82.1% (46/56) to gentamicin, 78.6% (44/56) to ciprofloxacin and 85.7% to meropenem, 51.8% (29/56) to amikacin, 82.1% (46/56) to cefazidime, 96.4% (54/56) to imipenem, 75.0% (42/56) to meropenem, 51.8% (29/56) to amikacin, 82.1% (46/56) to gentamicin, 78.6% (44/56) to ciprofloxacin and 85.7% to meropenem. This reality was previously reported in another Brazilian hospital [35]. In fact, resistance to carbapenem resistant strains exhibit a broad-spectrum resistance to beta-lactams and often present resistant phenotype to additional classes of drugs. Also, acquired ESBL and MBL genes typically group with other drug resistance determinants in the variable region of multi-resistance integrons [30-32]. Furthermore, P. aeruginosa isolated in Latin America, including Brazil, are reported as presenting the higher rates of antibiotic resistance [33]. P. aeruginosa strains resistant to polymyxins were not detected in this study. However, this result should be confirmed by a dilution method, considering that the disc diffusion technique, commonly used in clinical microbiology laboratories is reported to be an unreliable method for evaluating the susceptibility to polymyxins because these drugs diffuse poorly into agar [34].

In this study MBL genes were detected in 26.7% of isolates, indicating that despite the increasing significance of MBL production among P. aeruginosa, this was not the main mechanism of resistance to imipenem and/or meropenem. This reality was previously reported in another Brazilian hospital [35]. In fact, resistance to carbapenems in P. aeruginosa is due not only to the production of carbapenemases, but also to different mechanisms such as upregulation of multidrug efflux pumps, cell wall mutations leading to reduction in porin channels and production of different beta-lactamases [1,11]. Expression of these mechanisms, isolated or in combination, may cause variation in rates of resistance to imipenem and meropenem, observed in this study [5]. The twelve isolates presenting MBL phenotype by the DDST harbored MBL genes (bla<sub>SPM-1</sub> or bla<sub>IMP-1</sub>), confirming the efficacy of this method for the phenotypic detection of MBL producing strains [17,36].

Discussion
The pattern of multidrug resistance presented by the P. aeruginosa included in this study was expected, since carbapenem resistant strains exhibit a broad-spectrum resistance to beta-lactams and often present resistant phenotype to additional classes of drugs. Also, acquired ESBL and MBL genes typically group with other drug resistance determinants in the variable region of multi-resistance integrons [30-32]. Furthermore, P. aeruginosa isolated in Latin America, including Brazil, are reported as presenting the higher rates of antibiotic resistance [33]. P. aeruginosa strains resistant to polymyxins were not detected in this study. However, this result should be confirmed by a dilution method, considering that the disc diffusion technique, commonly used in clinical microbiology laboratories is reported to be an unreliable method for evaluating the susceptibility to polymyxins because these drugs diffuse poorly into agar [34].

In this study MBL genes were detected in 26.7% of isolates, indicating that despite the increasing significance of MBL production among P. aeruginosa, this was not the main mechanism of resistance to imipenem and/or meropenem. This reality was previously reported in another Brazilian hospital [35]. In fact, resistance to carbapenems in P. aeruginosa is due not only to the production of carbapenemases, but also to different mechanisms such as upregulation of multidrug efflux pumps, cell wall mutations leading to reduction in porin channels and production of different beta-lactamases [1,11]. Expression of these mechanisms, isolated or in combination, may cause variation in rates of resistance to imipenem and meropenem, observed in this study [5]. The twelve isolates presenting MBL phenotype by the DDST harbored MBL genes (bla<sub>SPM-1</sub> or bla<sub>IMP-1</sub>), confirming the efficacy of this method for the phenotypic detection of MBL producing strains [17,36].

Diversity of MBL among P. aeruginosa varies by regional areas [37]. In this study the 17.5% of the
### Table 1: Antimicrobial susceptibility of carbapenem resistant *P. aeruginosa* *

| No | Date | Unit   | Infection site | CAZ (R ≤ 14 S ≥ 18) | FEP (R ≤ 14 S ≥ 18) | TZP (R ≤ 17 S ≥ 18) | IPM (R ≤ 13 S ≥ 16) | MEM (R ≤ 15 S ≥ 22) | ATM (R ≤ 12 S ≥ 17) | GEN (R ≤ 14 S ≥ 15) | CIP (R ≤ 13 S ≥ 17) | LEV (R ≤ 13 S ≥ 17) | DDST | *bla* genotype |
|----|------|--------|----------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|------|----------------|
| Pa01 | 06/2009 | CI     | Urinary tract | 6 6 (10) 8 | 6 6 (10) 8 | 6 6 (17) 6 | 6 6 (15) 6 | 6 6 (18) 6 | 6 6 (17) 6 | 6 6 (17) 6 |
| Pa02 | 06/2009 | G-ICU  | Lung | 18 6 (18) 6 | 18 6 (12) 6 | 18 6 (16) 6 | 18 6 (15) 6 | 18 6 (16) 6 | 18 6 (15) 6 |
| Pa03 | 06/2009 | S-ICU  | Urinary tract | 20 6 (13) 6 | 20 6 (12) 6 | 20 6 (16) 6 | 20 6 (15) 6 | 20 6 (16) 6 | 20 6 (15) 6 |
| Pa04 | 06/2009 | G-ICU  | Lung | 6 6 (12) 6 | 6 6 (14) 6 | 6 6 (16) 6 | 6 6 (19) 6 | 6 6 (16) 6 | 6 6 (19) 6 |
| Pa05 | 07/2009 | E-ICU  | Blood | 6 6 (19) 6 | 6 6 (12) 6 | 6 6 (22) 6 | 6 6 (18) 6 | 6 6 (18) 6 | 6 6 (18) 6 |
| Pa06 | 07/2009 | E-ICU  | Lung | 6 6 (10) 11 | 6 6 (12) 14 | 6 6 (16) 12 | 6 6 (16) 12 | 6 6 (16) 12 | 6 6 (16) 12 |
| Pa07 | 07/2009 | N-Dep  | Lung | 6 6 6 6 | 6 6 16 6 | 6 6 6 6 | 6 6 6 6 | 6 6 6 6 |
| Pa08 | 07/2009 | C-Dep  | Urinary tract | 6 6 6 6 | 6 6 16 6 | 6 6 6 8 | 6 6 6 6 | 6 6 6 6 |
| Pa09 | 07/2009 | Outpatient | Urinary tract | 6 6 13 6 | 6 6 23 6 | 6 6 15 6 | 6 6 15 6 | 6 6 15 6 |
| Pa10 | 07/2009 | C-ICU  | Lung | 6 6 14 6 | 6 6 22 6 | 6 6 18 6 | 6 6 18 6 | 6 6 18 6 |
| Pa12 | 08/2009 | P-ICU  | Lung | 6 6 16 6 | 6 6 19 6 | 6 6 21 6 | 6 6 21 6 | 6 6 21 6 | 6 6 21 6 |
| Pa14 | 08/2009 | C-Dep  | Urinary tract | 6 6 10 6 | 6 6 15 6 | 6 6 18 6 | 6 6 18 6 | 6 6 18 6 |
| Pa17 | 08/2009 | P-ICU  | Lung | 17 6 16 13 | 17 6 17 16 | 6 6 6 6 | 6 6 6 6 | 6 6 6 6 | 6 6 6 6 |
| Pa18 | 08/2009 | E-ICU  | Lung | 6 6 6 6 | 6 6 12 6 | 6 6 17 6 | 6 6 17 6 | 6 6 17 6 | 6 6 17 6 |
| Pa19 | 09/2009 | P-ICU  | Lung | 6 6 6 6 | 6 6 14 19 | 23 23 23 10 | 23 23 23 10 | 23 23 23 10 | 23 23 23 10 |
| Pa22 | 08/2009 | SW     | Skin | 19 6 16 6 | 18 6 8 6 | 6 6 6 6 | 6 6 6 6 | 6 6 6 6 |
| Pa23 | 08/2009 | C-Dep  | Urinary tract | 6 6 6 6 | 6 6 6 6 | 6 6 18 6 | 6 6 18 6 | 6 6 18 6 |
| Pa27 | 08/2009 | P-ICU  | Catheter tip | 6 6 10 6 | 6 6 15 8 | 6 6 19 6 | 6 6 19 6 | 6 6 19 6 |
| Pa28 | 08/2009 | G-ICU  | Catheter tip | 6 6 6 6 | 6 6 14 6 | 6 6 13 6 | 6 6 13 6 | 6 6 13 6 |
| Pa29 | 09/2009 | C-Dep  | Lung | 23 6 17 6 | 22 12 6 | 6 6 6 6 | 6 6 6 6 | 6 6 6 6 |
| Pa30 | 09/2009 | P-ICU  | Eyes | 6 6 18 6 | 6 6 9 17 | 23 22 22 13 | 23 22 22 13 | 23 22 22 13 | 23 22 22 13 |
| Pa31 | 09/2009 | C-ICU  | Abdominal | 6 6 6 6 | 6 6 19 19 | 20 15 6 | 6 6 19 19 | 20 15 6 |
| Pa32 | 09/2009 | G-ICU  | Urinary tract | 6 6 12 6 | 6 6 19 13 | 6 6 19 13 | 6 6 19 13 |
| Pa33 | 09/2009 | P-ICU  | Lung | 6 6 6 6 | 6 6 13 19 | 22 20 6 | 6 6 13 19 | 22 20 6 |
| Pa34 | 09/2009 | C-ICU  | Bone | 6 6 6 6 | 6 6 12 6 | 6 6 6 6 | 6 6 6 6 | 6 6 6 6 |
| Pa35 | 09/2009 | C-ICU  | Lung | 18 6 21 6 | 6 6 6 6 | 12 6 12 6 | 12 6 12 6 | 12 6 12 6 | 12 6 12 6 |
| Pa36 | 09/2009 | N-Dep  | Lung | 6 6 18 6 | 6 6 13 6 | 6 6 17 6 | 6 6 17 6 | 6 6 17 6 |
| Pa37 | 09/2009 | S-ICU  | Urinary tract | 6 6 14 6 | 6 6 20 6 | 6 6 20 6 | 6 6 20 6 | 6 6 20 6 |
| Pa38 | 09/2009 | G-ICU  | Catheter tip | 25 6 14 6 | 24 21 6 | 6 6 6 6 | 6 6 6 6 | 6 6 6 6 |
| Pa39 | 09/2009 | G-ICU  | Catheter tip | 25 6 14 6 | 24 21 6 | 6 6 6 6 | 6 6 6 6 | 6 6 6 6 |

* bla genotype: *bla*<sub>CTX-M-2</sub>, *bla*<sub>IMP-1</sub>, *bla*<sub>CTX-M-2</sub>, *bla*<sub>MPC-1</sub>, *bla*<sub>SPM-1</sub>
| Patient ID | Date   | ICU   | Site          | CAZ | FEP | TZP | IMP | MEM | ATM | GEN | AK | CIP | LEV | DDTS | N      | P      |
|------------|--------|-------|---------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|--------|--------|
| Pa40       | 09/2009 | P-ICU | Urinary tract | 6   | 6   | 19  | 6   | 6   | 9   | 14  | 20  | 31  | 27  | N    | -      |        |
| Pa41       | 09/2009 | E-ICU | Lung          | 20  | 15  | 6   | 6   | 18  | 23  | 6   | 6   | 6   | 6   | N    | -      |        |
| Pa42       | 09/2009 | N-ICU | Eye           | 6   | 6   | 25  | 14  | 16  | 23  | 6   | 6   | 30  | 28  | N    | -      |        |
| Pa43       | 10/2009 | S-ICU | Lung          | 6   | 6   | 6   | 6   | 14  | 12  | 6   | 18  | 6   | 6   | N    | -      |        |
| Pa44       | 10/2009 | G-ICU | Lung          | 17  | 6   | 20  | 10  | 11  | 15  | 16  | 18  | 23  | 18  | N    | -      |        |
| Pa45       | 10/2009 | E-ICU | Skin          | 21  | 6   | 15  | 10  | 11  | 10  | 10  | 6   | 6   | 6   | 6   | N    | -      |        |
| Pa47       | 11/2009 | SW    | Urinary tract | 6   | 15  | 10  | 6   | 6   | 23  | 6   | 6   | 6   | 6   | P    | blaSPM-1 |        |
| Pa49       | 10/2009 | N-ICU | Urinary tract | 6   | 6   | 27  | 6   | 6   | 23  | 6   | 6   | 33  | 30  | P    | blaIMP-1 |        |
| Pa50       | 10/2009 | SC    | Bone          | 6   | 6   | 6   | 6   | 12  | 10  | 6   | 15  | 6   | 6   | N    | -      |        |
| Pa51       | 10/2009 | S-ICU | Urinary tract | 6   | 6   | 6   | 19  | 18  | 6   | 6   | 6   | 6   | N    | -      |        |
| Pa53       | 10/2009 | C-UTI | Lung          | 20  | 6   | 18  | 6   | 6   | 14  | 6   | 6   | 6   | 6   | N    | blaIMP-1, blaCTX-M 2 |
| Pa54       | 10/2009 | E-ICU | Urinary tract | 6   | 6   | 6   | 6   | 17  | 6   | 16  | 6   | 6   | P    | blaSPM-1 |        |
| Pa55       | 11/2009 | ER    | Urinary tract | 6   | 6   | 6   | 6   | 17  | 6   | 6   | 6   | 6   | N    | blaCTX-M 2 |        |
| Pa57       | 11/2009 | S-ICU | Urinary tract | 26  | 6   | 6   | 6   | 6   | 25  | 6   | 6   | 6   | 6   | N    | blaCTX-M 2 |        |
| Pa58       | 11/2009 | E-ICU | Urinary tract | 6   | 6   | 6   | 6   | 21  | 6   | 18  | 6   | 6   | P    | blaSPM-1 |        |
| Pa59       | 11/2009 | E-ICU | Lung          | 6   | 6   | 22  | 6   | 6   | 21  | 14  | 17  | 20  | 20  | P    | blaIMP-1, blaGES-1 |
| Pa60       | 11/2009 | ER    | Lung          | 6   | 6   | 10  | 12  | 6   | 8   | 6   | 6   | 6   | 6   | N    | blaIMP-1, blaCTX-M 2 |
| Pa61       | 11/2009 | N-Dep | Blood         | 6   | 6   | 6   | 6   | 10  | 6   | 6   | 6   | 6   | 6   | N    | bla IMP-1, blaCTX-M 2 |
| Pa62       | 11/2009 | E-ICU | Lung          | 6   | 6   | 6   | 13  | 6   | 11  | 6   | 6   | 6   | 6   | P    | blaIMP-1 |        |
| Pa63       | 11/2009 | E-ICU | Lung          | 6   | 6   | 15  | 6   | 6   | 6   | 19  | 6   | 6   | 6   | N    | -      |        |
| Pa64       | 11/2009 | N-Dep | Tendon       | 6   | 6   | 6   | 6   | 12  | 6   | 6   | 6   | 6   | 6   | N    | blaGES-5 |        |
| Pa65       | 11/2009 | S-ICU | Lung          | 6   | 6   | 6   | 6   | 11  | 6   | 6   | 6   | 6   | 6   | N    | -      |        |
| Pa66       | 11/2009 | C-ICU | Lung          | 6   | 6   | 15  | 6   | 6   | 14  | 13  | 20  | 30  | 25  | N    | -      |        |
| Pa67       | 11/2009 | ER    | Urinary tract | 6   | 6   | 6   | 6   | 15  | 13  | 6   | 6   | 6   | 6   | N    | -      |        |
| Pa69       | 11/2009 | E-ICU | Lung          | 6   | 6   | 6   | 19  | 6   | 21  | 6   | 6   | 20  | 6   | P    | blaSPM-1 |        |
| Pa70       | 11/2009 | E-ICU | Lung          | 6   | 6   | 6   | 11  | 11  | 12  | 6   | 6   | 6   | 6   | N    | -      |        |
| Pa71       | 11/2009 | E-ICU | Lung          | 6   | 6   | 6   | 6   | 11  | 6   | 6   | 6   | 6   | 6   | N    | blaCTX-M 2 |        |

**CAZ**, ceftazidime; **FEP**, cefepime; **TZP**, piperacillin-tazobactam; **IMP**, imipenem; **MEM**, meropenem; **ATM**, aztreonam; **GEN**, gentamicin; **AK**, amikacin; **CIP**, ciprofloxacin; **LEV**, levofloxacin; **DDTS**, double disc synergy test to detect MBL production. **N**, negative; **P**, positive; **ER**, emergency room; **E-ICU**, emergency intensive care unit; **G-ICU**, general intensive care unit; **S-ICU**, semi-intensive care unit; **C-ICU**, cardiology intensive care unit; **P-ICU**, pediatrics intensive care unit, **N-ICU**, neonatal intensive care unit **N-Dep**, neurology department; **C-Dep**, cardiology department; **SC**, surgical ward, **CI**, cancer institute; **R**, resistant; **S**, susceptible.
carbapenem resistant isolates presented the bla\textsubscript{SPM-1} gene, and bla\textsubscript{IMP-1} was detected in 10.5% of the isolates. SPM-1 is in fact the most prevalent MBL in Brazil [38]. In a different way, IMP-1 producing strains have been reported in various Brazilian hospitals in diverse rates [35,39,40].

Molecular typing by PFGE showed a wide diversity of patterns. All isolates exhibiting bla\textsubscript{SPM-1}, a chromosomally located gene [41,42] presented high coefficient of similarity and closely related PFGE patterns, suggesting a close genetic relationship. This is in agreement with previously described data, showing that the Brazilian SPM-1-producing \textit{P. aeruginosa} are probably derived from a single clone [43]. According to the same study, even a recent genomic variety recently observed among various SPM-1-producing \textit{P. aeruginosa} isolates is result of the accumulation of mutations along the time.

Occurrence of bla\textsubscript{IMP-1} in \textit{P. aeruginosa} described in this study is likely a result of gene horizontal transferring, since isolates harboring bla\textsubscript{IMP-1} belong to five different clusters. Dissemination of bla\textsubscript{IMP} among Gram-negative pathogens is mediated by mobile elements of DNA, explaining why the same gene might be detected in different strains. The genes for IMP enzymes are often carried as cassettes within integrons, which facilitate recombination and facilitate rapid horizontal transferring [44-46].

The coexistence of bla\textsubscript{IMP-1} with bla\textsubscript{CTX-M-2} in \textit{P. aeruginosa} was, at the best of our knowledge, detected for the first time. Interestingly, the three isolates presenting this combination of genes did not provide a positive result in the DDST test, and were the only bla\textsubscript{IMP-1} carriers in which MBL phenotypic detection was unsuccessful. Since ceftazidime is poorly hydrolyzed by CTX-M-2 [31], we could not assume that inactivation of this antimicrobial, used as substrate, may have been responsible for this result. However, simultaneous production of MBLs and ESBLs by the same strain is known to promote further complexity in phenotypic detection [7,47,48]. This result emphasizes the importance of molecular methods for the identification of antimicrobial resistance in multidrug resistant pathogenic bacteria. In this matter, detection of resistance genes by PCR may provide clinically relevant information with positive impact in patient prognosis [18].

The detection of bla\textsubscript{CTX-M-2}, bla\textsubscript{GES-1} and bla\textsubscript{GES-5} in this study reflects the recent emergence of ESBLs in \textit{P. aeruginosa} as result of the great dissemination capability exhibited by these genes that occur mostly as part of integron structures on mobile transmissible genetic elements [49-52]. Location of bla\textsubscript{CTX-M-2} in \textit{P. aeruginosa} is believed to be a result of their transfer from \textit{Enterobacteriaceae} [51]. Recently, a high prevalence of \textit{K. pneumoniae} harboring bla\textsubscript{CTX-M-2} in the same hospital was reported [21], and this may have been the reservoir for horizontal transmission.

Regarding GES-type ESBLs, although these enzymes are not considered as primary β-lactamases in \textit{P. aeruginosa}, acquisition in conditions of antimicrobial pressure may be beneficial [52]. The bla\textsubscript{GES-1} was detected in co-existence with bla\textsubscript{IMP-1}, and bla\textsubscript{GES-5} was detected in a strain resistant to imipenem and meropenem, but
presenting no MBL phenotype. Considering that GES-5 presents enhanced hydrolyse activity against carbapenems [10], it is likely that GES-5 production contributed for the carbapenem resistance in this isolate.

**Conclusion**
Production of MBLs was not the main mechanism of resistance to carbapenems among the studied strains. However, IMP-1 is disseminated among different strains of carbapenem resistant *P. aeruginosa*, and intra-hospital spread of SPM-1 producing strains was observed. The detection of *blaCTX-M-2, blaGES-1* and *blaGES-5* and the unique coexistence of *blaCTX-M-2* with *blaIMP-1* and *blaGES-1* with *blaIMP-1* exemplify the extraordinary ability presented by *P. aeruginosa* to acquire multiple resistance mechanisms.

Clonal dissemination of multidrug resistant *P. aeruginosa* within the hospital was inferred by the observation of strains presenting the identical PFGE profiles infecting different patients, and the occurrence of clonal dissemination in different ICUs and wards. This finding enhances the necessity of better observance of infection control practices, to prevent further dissemination of this challenging pathogen.

**Additional file**

**Additional file 1: Gen Bank Accession Number – Sup Material.**

**Competing interests**
The authors declare that they have no competing interests.

**Authors’ contribution**
MP, TC and MCLN carried out the molecular genetic studies, participated in the sequence alignment. MGL, FGR, MTGA, MLN and MCLN participated in the design of the study. MGL, MTGA and MP collected and characterized the isolates. MLN, MTGA and FGR analyzed the results. MP, MLN and MCLN drafted the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**
This work was supported by a FAPESP grant to MCLN. MLN is supported by FAPESP and CNPq Grants. MLN is recipient of a CNPq Fellowship. MP is a recipient of a CAPES Scholarship.

**Author details**
1. Laboratório de Microbiologia. Departamento de Doenças Dermatológicas, Infectiosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP, Brazil.
2. Programa de Pós Grau em Microbiologia, Universidade Estadual Paulista Júlio de Mesquita Filho, UNESP, Campus de São José do Rio Preto, Brazil.
3. Laboratório Central do Hospital de Base de São José do Rio Preto, São José do Rio Preto, SP, Brazil.
4. Laboratório de Pesquisa em Virologia. Departamento de Doenças Dermatológicas, Infectiosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP, Brazil.

Received: 13 March 2012 Accepted: 24 July 2012
Published: 3 August 2012

**References**
1. Slama TG: Gram-negative antibiotic resistance: there is a price to pay. *Crit Care* 2008, 12(4):1–7.
2. Lister PD, Wolter DJ, Hanson ND: Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev* 2009, 22(4):582–610.
3. Mesasor N, Nordmann P, Pšelis P, Rousseau-Delvallez M, Van Eldere J, Giupczynski Y, Van Larehrem Y, Jacobs F, Lebecque P, Maffuo A, Tulkens PA, Van Bambekhe F: *Pseudomonas aeruginosa*: resistance and therapeutic options at the turn of the new millennium. *Clin Microbiol Infect* 2007, 13(6):560–578.
4. Nordmann P, Naas T, Fortinneau N, Poilert L: Superbugs in the coming new decade; multdrug resistance and prospects for treatment of *Staphylococcus aureus*, *Enterococcus spp*. and *Pseudomonas aeruginosa* in 2010. *Eur Opin Microbiol* 2007, 10(5):468–440.
5. Strateva T, Yordanov O: *Pseudomonas aeruginosa* – a phenomenon of bacterial resistance. *J Med Microbiol* 2009, 58(9):1133–1148.
6. Tam VH, Rogers CA, Chang KT, Weston JS, Caio JS, Carey KW: Impact of multidiagnostic-resistant *Pseudomonas aeruginosa* bacteremia on patient outcomes. *Antimicrob Agents Chemother* 2010, 54(9):3717–3722.
7. Giupczynski Y, Borgaerts P, Deplano A, Béhin C, Huang TD, Van Eldere J, Rodriguez-Villalobos H: Detection and characterization of class A extended-spectrum-beta-lactamase-producing *Pseudomonas aeruginosa* isolates in Belgian hospitals. *J Antimicrob Chemother* 2010, 65(5):866–871.
8. Lin SP, Liu MF, Lin CF, Shi ZY: Phenotypic detection and polymerase chain reaction screening of extended-spectrum β-lactamases produced by *Pseudomonas aeruginosa* isolates. *J Microbiol Immunol Infect* 2012, 45(3):200–207. [Epub ahead of print].
9. Bush K: New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. *Clin Infect Dis* 2001, 32(7):1085–1089.
10. Zhao WH, Hu ZQ: Beta-lactamases identified in clinical isolates of *Pseudomonas aeruginosa*. *Crit Rev Microbiol* 2010, 36(3):245–258.
11. Shu JC, Chia JH, Siu KF, Huang SH, Su LH, Wu TL: Interplay between mutational and horizontally acquired resistance mechanisms and its association with carbapenem resistance amongst extensively drug-resistant *Pseudomonas aeruginosa* (XDR-PA). *Int J Antimicrob Agents* 2012, 39(3):217–222.
12. Weidhagen GF, Poilert L, Nordmann P: Ambler class A extended-spectrum beta-lactamases in *Pseudomonas aeruginosa*: novel developments and clinical impact. *Antimicrob Agents Chemother* 2003, 47(8):2385–2392.
13. Poilert L, Doccquier JD, De Luca F, Verlindel AE, Ide L, Rossolini GM, Nordmann P: BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2010, 54(1):533–535.
14. Tian GB, Adams-Haduch JM, Bogdanovich T, Wang HN, Doi Y: PME-1, an extended-spectrum β-lactamase identified in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2011, 55(8):2710–2712.
15. Picco RC, Poilert L, Gales AC, Nordmann P: Diversity of beta-lactamases produced by ceftazidime-resistant *Pseudomonas aeruginosa* isolates causing bloodstream infections in Brazil. *Antimicrob Agents Chemother* 2009, 53(9):3908–3913.
16. Zhao WH, Chen G, Ito R, Hu ZQ: Resistance of relevance levels to carbapenems and integron-borne *blaIMP-1, blaIMP-7*, *blaIMP-10* and *blaVIM-2* in clinical isolates of *Pseudomonas aeruginosa*. *J Med Microbiol* 2009, 58(8):1080–1085.
17. Picco RC, Andrade SS, Niccolitti AG, Campana EH, Moraes GC, Mendes RE, Gales AC: Metallo-β-Lactamase Detection: Comparative Evaluation of Double-Disk Synergy versus Combined Disk Tests for IMP-, GIM-, SIM-, SPM-, or VIM-Producing Isolates. *J Clin Microbiol* 2008, 46(8):2628–2637.
18. Tienover VC: Potential impact of rapid diagnostic tests on improving antibiotic uses. *Ann NY Acad Sci* 2010, 1213(70–80. [Epub ahead of print].
19. Endimiani A, Hujer KM, Hujer AM, Kurz S, Jacobs MR, Perlin DS, Bonomo RA: Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? *Clin Infect Dis* 2011, 52(5):573–583.
20. Performance standards for antimicrobial susceptibility testing. 19th informational supplement, M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
21. Toffolino FM, Polotto M, Nogueira ML, Lincopan N, Neves P, Marmízka EM, Remeli GA, De Almeida MT, Rubbo FG, Nogueira MC: High Prevalence of *blaCTX-M* Extended Spectrum Beta-Lactamase Genes in Kēōkea pneumonieae Isolates from a Tertiary Care Hospital. First report of *blaIMP-1*.7.
22. Yan JJ, Hsuieh P, Ko W, Luh W, Tsai S, Wu HM, Wu JJ: Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 2001, 45(8):2224–2228.
23. Yigit H, Quevano AM, Anderson GJ, Dornenech-Sanchez A, Biddle W, Steward CD, Alberti S, Bush K, Tenover FC: Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001, 45(4):1151–1161.
24. Poirel L, Naas T, Delphine N, Collet L, Bellaïs S, Cavallo JD, Nordmann P: Characterization of VIM-2, a Carbapenem-Hydrolyzing Metallo-β-Lactamase and Its Plasmid- and Integron-Born Gene from a Pseudomonas aeruginosa Clinical Isolate in France. Antimicrob Agents Chemother 2000, 44(4):891–897.
25. Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL: Detection of Pseudomonas aeruginosa producing metallo-beta-lactamas in a large centralized laboratory. J Clin Microbiol 2005, 43(3):129–3135.
26. Sambrook J, Russel DW: Purification of PCR products in preparation for cloning. In Molecular Cloning: a Laboratory Manual, Volume Volume 2. 3rd edition. New York: Cold Spring Harbor Laboratory Press; 2001:8.25–8.26.
27. Silbert S, Pfaller MA, Hollis RJ, Barth AL, Sader HS: Evaluation of three molecular typing techniques for nonfermentative Gram-negative bacilli. Infect Control Hosp Epidemiol 2004, 25(10):847–851.
28. Tsutui A, Suzuki S, Yamaoka K, Matsu M, Konda T, Marui E, Takahashi K, Arakawa Y: Genotypes and infection sites in an outbreak of multidrug-resistant Pseudomonas aeruginosa. J Hosp Infect 2011, 78(4):317–322.
29. Tenover FC, Arbet RD, Goering RV, Micksen PA, Murray BE, Persing DH, Walmsley RS: Interpreting Chromosomal DNA Restriction Patterns Produced By Pulsed-Field Gel Electrophoresis: Criteria For Bacterial Strain Typing. J Clin Microbiol 1995, 33(9):2233–2239.
30. Lagatolla C, Tonić EA, Monti-Bragadin C, Dolzani L, Gombac F, Beard C, Edalucci E, Gonnechetti F, Rossolini GM: Endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo-beta-lactamase determinants in European hospital. Emerg Infect Dis 2004, 10(6):535–538.
31. Paterson DL, Bonomo RA: Extended-spectrum beta-lactamas: a clinical update. Clin Microbiol Rev 2005, 18(4):657–686.
32. Maltzou HC: Metallo-β-Lactamase in Gram-negative bacteria: introducing the era of pan-resistance? Int J Antimicrob Agents 2008, 33(2):305–407.
33. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR: Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis 2007, 57(17):1–3.
34. van der Heijden IM, Levin AS, De Pedri EH, Fung L, Rossi F, Duboc G, Barone AA, Costa SF: Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins. Ann Clin Microbiol Antimicrob 2007, 6(8).
35. Marra AR, Pereira CA, Gales AC, Menezes LC, Cal RG, De Souza JM, Edmond MB, Faro C, Wey SB: Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology and clinical outcomes. Antimicrob Agents Chemother 2008, 52(1):388–390.
36. Franco MR, Calafta-Filho HH, Buratini MN, Rossi F: Metallo-beta-lactamasas among imipenem-resistant Pseudomonas aeruginosa in a Brazilian university hospital. Clinics 2010, 65(9):825–829.
37. Comaglia G, Gamarellou H, Rossolini GM: Metallo-β-lactamasas: a last frontier for β-lactams? Lancet Infect Dis 2011, 11(5):381–393.
38. Gales AC, Menezes LC, Silbert S, Sader HS: Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. J Antimicrob Agents Chemother 2003, 52(4):699–702.
39. Sader HS, Reis AO, Silbert S, Gales AC: IMPs, VIMs and SPMs: the diversity of metallo-beta-lactamases produced by Pseudomonas aeruginosa. Clin Microbiol Infect 2005, 11(1):73–76.
40. Martins AF, Zawacki AP, Gaspareto PB, Barth AL: Dissemination of Pseudomonas aeruginosa producing SPM-1-like and IMP-1-like metallo-beta-lactamases in hospitals from southern Brazil. Infectious Disease 2007, 35(6):457–460.
41. Poirel L, Magalhaes M, Lopes M, Nordmann P: Molecular analysis of metallo-β-lactamase gene blaoxac-1 surrounding sequences from disseminated Pseudomonas aeruginosa isolates in Recife, Brazil. Antimicrob Agents Chemother 2004, 48(4):1406–1409.
42. Salabi AE, Toleman MA, Weeks J, Bruderer T, Frei R, Walsh TR: First report of the metallo-beta-lactamase SPM-1 in Europe. Antimicrob Agents Chemother 2010, 54(1):582.
43. Silva FM, Carmo MS, Silbert S, Gales AC: SPM-1-producing Pseudomonas aeruginosa: analysis of the ancestor relationship using multilocus sequence typing, pulsed-field gel electrophoresis, and automated ribotyping. Microb Drug Resist 2011, 17(2):215–220.
44. Livermore DM: Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare. Clin Infect Dis 2002, 34(5):634–640.
45. Walsh TR, Toleman MA, Poirel L, Nordmann P: Metallo-β-Lactamases: the Quiet before the Storm. Clin Microbiol Rev 2005, 18(2):305–325.
46. Walsh TR: Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010, 36(3):8–14.
47. Doccuier JD, Luzzaro F, Arico G, Nicolò A, Rossolini GM: Multidrug-resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum serine-beta-lactamase and VIM-2 metallo-beta-lactamase. Emerg Infect Dis 2001, 7(5):910–911.
48. Woodford N, Zhang J, Kaufmann ME, Yarde S, Tomas Mdel M, Faris C, Vardhan MS, Dawson S, Cotterill SL, Livermore DM: Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum beta-lactamases in the United Kingdom. J Antimicrob Agents Chemother 2008, 62(6):126S–1268.
49. Mansour W, Dahmen S, Poirel L, Charfi K, Bezteide B, Boujaafar N, Boulagoue O: Emergence of SHV-2a extended-spectrum beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a university hospital in Tunisia. Microb Drug Resist 2009, 15(4):295–301.
50. Naas T, Cuzon G, Villegas MW, Largeteau MQ, Quinon JP, Nordmann P: Genetic structures at the origin of acquisition of the beta-lactamase blaoxac gene. Antimicrob Agents Chemother 2008, 52(4):1257–1263.
51. Picco RC, Poirel L, Gales AC, Nordmann P: Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009, 53(5):2225–2226.
52. Labuschagne C, J, Weldhagen GF, Ehlers MM, Dove MG: Emergence of class 1 integron-associated GES-5 and GES-5-like extended-spectrum beta-lactamases in clinical isolates of Pseudomonas aeruginosa in South Africa. Int J Antimicrob Agents 2008, 31(6):527–530.

doi:10.1186/1471-2334-12-176
Cite this article as: Polotto et al. Detection of P. aeruginosa harboring blaoxac-mp, blaoxac-dmp, and blaoxac-gmp and blaoxac-mp, and blaoxac-gmp, causing infections in Brazilian tertiary-care hospital. BMC Infectious Diseases 2012, 12:176.